Tempus AI, Inc. (TEM) Shares Outstanding: 0.17
Is Tempus AI, Inc.’s shares outstanding high or low?
Tempus AI, Inc.'s shares outstanding of 0.17 is in line with its 5-year average of 0.17, near the high end of its 5-year range (0.15–0.17).
3.61% above its 12-month average of 0.17.
TEM Shares Outstanding Chart
TEM Average Shares Outstanding Chart
TEM Current vs Average Shares Outstanding Chart
TEM Shares Outstanding Metrics
SHARES OUTSTANDING
0.17
SHARES OUTSTANDING AVG TTM
0.17
SHARES OUTSTANDING AVG 3Y
0.17
SHARES OUTSTANDING AVG 5Y
0.17
SHARES OUTSTANDING AVG 10Y
0.17
SHARES OUTSTANDING AVG 15Y
0.17
SHARES OUTSTANDING AVG 20Y
0.17
CURRENT VS TTM AVG
+3.61%
CURRENT VS 3Y AVG
+5.55%
CURRENT VS 5Y AVG
+4.54%
CURRENT VS 10Y AVG
+5.08%
CURRENT VS 15Y AVG
+5.08%
CURRENT VS 20Y AVG
+5.08%
Share Structure
Shares Outstanding
174.26M
Float Shares
N/A
Stock Price
$49.59
Market Cap
$8.7B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 174.26M | +7.49% |
| 2024 | 162.12M | +5.15% |
| 2023 | 154.17M | -9.24% |
| 2022 | 169.88M | +0.00% |
| 2021 | 169.88M | +0.00% |
| 2020 | 169.88M | +5.71% |
| 2019 | 160.71M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
Tempus AI, Inc. Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Shares Outstanding FAQ
- What is the shares outstanding for Tempus AI, Inc. (TEM)?
- The shares outstanding for TEM stock is 0.17.
- Is Tempus AI, Inc.'s shares outstanding high or low?
- Tempus AI, Inc.'s shares outstanding of 0.17 is in line with its 5-year average of 0.17, near the high end of its 5-year range (0.15–0.17).
- What is the TTM average shares outstanding for Tempus AI, Inc. (TEM)?
- The TTM average shares outstanding for TEM stock is 0.17.
- What is the 3Y average shares outstanding for Tempus AI, Inc. (TEM)?
- The 3Y average shares outstanding for TEM stock is 0.17.
- What is the 5Y average shares outstanding for Tempus AI, Inc. (TEM)?
- The 5Y average shares outstanding for TEM stock is 0.17.
- What is the 10Y average shares outstanding for Tempus AI, Inc. (TEM)?
- The 10Y average shares outstanding for TEM stock is 0.17.
- What is the 15Y average shares outstanding for Tempus AI, Inc. (TEM)?
- The 15Y average shares outstanding for TEM stock is 0.17.
- What is the 20Y average shares outstanding for Tempus AI, Inc. (TEM)?
- The 20Y average shares outstanding for TEM stock is 0.17.
Tempus AI, Inc. Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 0.17 |
| 2024-12-31 | 0.16 |
| 2023-12-31 | 0.15 |
| 2022-12-31 | 0.17 |
| 2021-12-31 | 0.17 |
| 2020-12-31 | 0.17 |
| 2019-12-31 | 0.16 |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky